#MedTwitter A patient is admitted to the hospital with sepsis. You are ordering DVT prophylaxis. CrCl is 60 ml/min and BMI 43. What do you start as prophylaxis?
2/In this study of hospitalized patients with BMI >40, use of standard LMWH dosing (40mg daily) rarely resulted in target anti-Xa level.
https://pubmed.ncbi.nlm.nih.gov/22565589/
https://pubmed.ncbi.nlm.nih.gov/22565589/
Enoxaparin ppx superior to heparin in most outcomes per 2014 Cochrane review including risk of DVT (OR 0.77) and major bleeding (OR 0.43) although no difference in mortality.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491079/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491079/
4/ Higher absolute risk of HIT with UFH (2.6%) than with LMWH (0.2%). https://pubmed.ncbi.nlm.nih.gov/15985543/
5/This recent study in pts with BMI>40 showed that WB statically similar compared to BID dosing of enoxaparin. No significant bleeding events noted.
https://pubmed.ncbi.nlm.nih.gov/33400099/
https://pubmed.ncbi.nlm.nih.gov/33400099/
Conclusions:
1. LMWH (enoxaparin) superior to UFH (heparin) in outcomes and lower risk of HIT.
2. In pts with BMI >40, standard enoxaparin dosing (40mg daily) rarely led to target anti-Xa levels.
3. Use of enoxaparin 40mg BID or weight based dosing similar outcomes.
1. LMWH (enoxaparin) superior to UFH (heparin) in outcomes and lower risk of HIT.
2. In pts with BMI >40, standard enoxaparin dosing (40mg daily) rarely led to target anti-Xa levels.
3. Use of enoxaparin 40mg BID or weight based dosing similar outcomes.